CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.05B, above the global median of $1.18B
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.05BUSDvs all stocks (USD)
Revenue (TTM)
494.61MUSDvs all stocks (USD)
Profit Margin
-36.31%Beta
0.2160xvs all stocks
52-Week Change
-31.55%vs all stocks
Market Capitalization
2.05BUSDvs all stocks (USD)
Enterprise Value
3.41BUSDvs all stocks (USD)
Forward P/E
25.18xPrice to Sales (TTM)
4.15xEnterprise to Revenue
6.89xEnterprise to EBITDA
44.99xGross Margin
50.65%Profit Margin
-36.31%Operating Margin
-11.05%Return on Assets (TTM)
2.19%Revenue (TTM)
494.61MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.68USDUpdated Sep 26, 2026Quarterly Revenue Growth
-38.90%Gross Profit (TTM)
300.04MUSDvs all stocks (USD)
EBITDA (TTM)
109.61MUSDvs all stocks (USD)
Net Income (TTM)
-179.59MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-38.94%Operating Cash Flow (TTM)
-198.70MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-123.13MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
586.32MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
235.56MUSDFY2025 · Dec 31, 2025Gross Profit
350.76MUSDFY2025 · Dec 31, 2025Operating Income
78.21MUSDvs all stocks (USD)
Pre-tax Income
136.35MUSDFY2025 · Dec 31, 2025Income Tax Expense
108.43MUSDFY2025 · Dec 31, 2025Net Income
27.92MUSDFY2025 · Dec 31, 2025EBIT
273.22MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
109.61MUSDFY2025 · Dec 31, 2025Research & Development
184.19MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
84.92MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-2.58MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.77MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
136.87MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.1000USDFY2025 · Dec 31, 2025EPS (Diluted)
0.1000USDFY2025 · Dec 31, 2025Basic Shares Outstanding
279.19MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
279.19MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
27.92MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-48.38MUSDFY2025 · Dec 31, 2025Free Cash Flow
-112.85MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
172.36MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
27.92MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
37.85MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
108.43MUSDFY2025 · Dec 31, 2025Stock-based Compensation
7.38MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-67.00MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-2.08MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-160.87MUSDFY2025 · Dec 31, 2025Capital Expenditures
-64.47MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-31.66MUSDFY2025 · Dec 31, 2025Net Acquisitions
-8.09MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-72.56MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
233.48MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-35.79MUSDFY2025 · Dec 31, 2025Other Financing Charges
-9.34MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
270.83MUSDFY2025 · Dec 31, 2025Shares Outstanding
356.82MSharesUpdated Sep 26, 2026Float Shares
140.79MSharesUpdated Sep 26, 2026Shares Short
5.81MSharesUpdated Sep 26, 2026Short Ratio
5.80daysvs all stocks
Short % of Shares Outstanding
3.61%vs all stocks
% Held by Insiders
59.68%vs all stocks
% Held by Institutions
12.76%vs all stocks
Total Cash (MRQ)
142.75MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.4000USDUpdated Sep 26, 2026Total Debt (MRQ)
1.45BUSDvs all stocks (USD)
Current Ratio (MRQ)
1.65xBook Value per Share (MRQ)
-0.5370USDUpdated Sep 26, 2026Total Assets
1.49BUSDvs all stocks (USD)
Total Current Assets
574.01MUSDFY2025 · Dec 31, 2025Total Liabilities
1.77BUSDFY2025 · Dec 31, 2025Total Non-current Assets
913.08MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.47BUSDFY2025 · Dec 31, 2025Total Current Liabilities
304.08MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
172.36MUSDFY2025 · Dec 31, 2025Accounts Receivable
69.74MUSDFY2025 · Dec 31, 2025Inventory
220.05MUSDFY2025 · Dec 31, 2025Accounts Payable
126.12MUSDFY2025 · Dec 31, 2025Short-term Debt
49.00MUSDFY2025 · Dec 31, 2025Deferred Revenue
30.36MUSDFY2025 · Dec 31, 2025Long-term Debt
1.40BUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.93MUSDFY2025 · Dec 31, 2025Retained Earnings
-2.41BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-284.49MUSDvs all stocks (USD)
52-Week Low
2.94USDUpdated Sep 26, 202652-Week High
9.04USDUpdated Sep 26, 202652-Week Change
-31.55%vs all stocks
Beta
0.2160xvs all stocks
50-Day MA
4.44USDUpdated Sep 26, 2026200-Day MA
4.17USDUpdated Sep 26, 2026Avg 10-Day Volume
1.47MSharesUpdated Sep 26, 2026Avg 30-Day Volume
1.17MSharesUpdated Sep 26, 2026Diluted EPS (TTM)
-0.6200USDUpdated Sep 26, 2026Other Income / Expense
201.45MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.51Profit Margin: -0.36
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $2.05B, above the global median of $1.18BNotable
Market cap (USD): 2,051,697,968Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Trevi Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Voronoi, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vericel Corporation
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Vazyme Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inspire Medical Systems, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kodiak Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Kangtai Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ab&B Bio-Tech Co., Ltd. (JS)
Tier 1ProductionApproval-Gated PipelineRule